Arvinas (NASDAQ:ARVN) Reaches New 52-Week Low – Time to Sell?

Arvinas, Inc. (NASDAQ:ARVN) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $15.53 and last traded at $16.02, with a volume of 42764 shares. The stock had previously closed at $16.23.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ARVN. Stifel Nicolaus dropped their price objective on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. BTIG Research began coverage on shares of Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research report on Tuesday, February 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Finally, Stephens began coverage on shares of Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price objective on the stock. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $60.00.

Arvinas Stock Down 1.1 %

The stock’s 50 day moving average is $18.36 and its two-hundred day moving average is $22.66. The company has a market capitalization of $1.10 billion, a PE ratio of -5.77 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm earned ($2.53) earnings per share. On average, sell-side analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,572 shares of company stock valued at $695,030 over the last three months. 5.23% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arvinas

Several hedge funds and other institutional investors have recently bought and sold shares of ARVN. JPMorgan Chase & Co. lifted its position in shares of Arvinas by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after buying an additional 367,343 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in Arvinas in the 3rd quarter valued at $9,989,000. SG Americas Securities LLC lifted its holdings in Arvinas by 228.8% in the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock valued at $622,000 after purchasing an additional 22,564 shares in the last quarter. Wasatch Advisors LP lifted its holdings in Arvinas by 58.3% in the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after purchasing an additional 160,510 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Arvinas by 198.9% in the 3rd quarter. Barclays PLC now owns 121,699 shares of the company’s stock valued at $2,998,000 after purchasing an additional 80,984 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.